Novel therapies - IMID Co-morbidities

Area of Science:

• Rheumatology
• Cardiology
• Endocrinology

Background:

• Immune-mediated inflammatory diseases (IMID) are frequently associated with cardiovascular diseases (CVD) and metabolic syndrome.
• Inflammation, particularly adipokine-mediated, plays a key role in obesity and cardiovascular-kidney-metabolic (CKM) syndrome pathogenesis.
• Interactions between IMID, CVD, metabolic syndrome, and their treatments necessitate active management by rheumatologists.

Purpose of the Study:

• To review novel therapeutics for metabolic comorbidities and their pleiotropic benefits in IMID.
• To discuss the repurposing of conventional drugs, like colchicine, for CVD management and their relevance in IMID.
• To highlight the intersection of novel metabolic and anti-inflammatory therapies in managing complex patient populations.

Main Methods:

• Literature review of novel therapeutics for metabolic comorbidities.
• Analysis of anti-inflammatory drugs' efficacy in CVD and IMID.
• Discussion of drug repurposing and adjunctive therapeutic strategies.

Main Results:

• Novel metabolic therapeutics show anti-inflammatory and immunomodulatory effects beneficial for IMID.
• Colchicine is the first anti-inflammatory drug approved for CVD, demonstrating efficacy.
• Repurposed drugs and novel agents offer adjunctive management for CVD and metabolic syndrome in IMID patients.

Conclusions:

• Integrated management of IMID with CVD and metabolic syndrome is crucial.
• Novel therapeutics and repurposed anti-inflammatory drugs represent promising adjunctive strategies.
• Rheumatologists play a vital role in managing these multifaceted patient conditions.